About Abingworth
Abingworth is a venture capital firm founded in 1973. It is primarily based out of London, United Kingdom. As of Sep 2026, Abingworth is an active investor, having invested in 134 companies, with 5 new investments in the last 12 months. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Enterprise Applications. Most recently it participated in the $***** Series A round of R1 Therapeutics Overall, Abingworth portfolio has seen 30 IPOs and 54 acquisitions including key companies like Alnylam, Vaxcyte and Vera Therapeutics. A lot of funds co-invest with Abingworth, with names like Novo Holdings sharing a substantial percentage of its portfolio. Abingworth has team of 20 people including 8 partners.Key Metrics
Team Members
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B & 8 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Deals in last 12 months
Abingworth's List of Top Investments
Abingworth has a portfolio of 134 companies. Their most notable investments are in Wugen and Pathwork Diagnostics.Their portfolio spans across United States, United Kingdom, Switzerland and 11 more locations. They have invested in Life Sciences, High Tech, Enterprise Applications and 4 other sectors, across stages such as Series A, Series B and 8 more. Here is the list of top investments by Abingworth:1. Alnylam
Developer of RNA interference-based therapeutics for multiple disorders. Its pipeline includes drugs that are used to treat hereditary ATTR Amyloidosis, acute hepatic porphyria, and treating hypercholesterolemia. It also develops drugs for cardiometabolic diseases, infectious diseases, central nervous system, and ocular diseases.
Key facts about Alnylam
- Founded Year: 2002
- Location: Cambridge (United States)
- Annual Revenue: $1B+ as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $17M
- Employee Count: 3,095 as on Sep 30, 2026
- Investors: Colt Ventures, Atlas Venture and 14 Others
- Latest Funding Round: Post IPO, Aug 17, 2020, $*****
- Highlight: Public
2. Vaxcyte
Developer of vaccines to treat infectious diseases. The company uses the cell-free protein synthesis platform called XpressCFTM along with the company's proprietary knowledge base to design and produce protein carriers and antigens for site-specific conjugation (building blocks of vaccines) for developing antigens and pneumococcal conjugate vaccines (VAS-24). It is also developing vaccines for invasive, pneumococcal diseases, otitis media, strep infections, and periodontitis.
Key facts about Vaxcyte
- Founded Year: 2013
- Location: Foster City (United States)
- Stage: Public
- Total Funding till date: $283M
- Employee Count: 595 as on Sep 30, 2026
- Investors: HTIF, Foresite Capital and 16 Others
- Latest Funding Round: Series D, Apr 03, 2020, $*****
- Highlight: Public
Developer of therapeutic solutions for the treatment of immunological and inflammatory diseases. The company has an atacicept novel biologic drug that is a human recombinant fusion protein that helps in treating IgA nephropathy which is a rare autoimmune disease. It contains a soluble TACI receptor that binds to the cytokines BLyS and APRIL to promote B-cell survival and autoantibody production for the treatment of autoimmune diseases.
Key facts about Vera Therapeutics
- Founded Year: 2016
- Location: San Francisco (United States)
- Stage: Public
- Total Funding till date: $117M
- Employee Count: 359 as on Aug 31, 2026
- Investors: Fidelity Investments, Longitude Capital and 13 Others
- Latest Funding Round: Series C, Oct 29, 2020, $*****
- Highlight: Public
4. Personalis
Provider of genomic sequencing and diagnosis software for the healthcare industry. It provides services for the sequencing of DNA, RNA, augmented exome, and targeted transcriptome. It has developed products for precision oncology such as the ImmunoID NeXT platform that provides an end-to-end solution for precision diagnosis. It provides immune-related information using analytical algorithms and checking immune checkpoints. Other products developed by the company are RepertoireID that analysis tumor samples of patients, ImmunogenomicsID, and NeoantigenID.
Key facts about Personalis
- Founded Year: 2011
- Location: Menlo Park (United States)
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $87.3M
- Employee Count: 426 as on Sep 30, 2026
- Investors: TriplePoint Capital, Abingworth and 5 Others
- Latest Funding Round: Post IPO, Dec 19, 2024, $*****
- Highlight: Acquired
5. AdvanCell
Radiopharmaceutical company developing targeted alpha therapies for cancer treatment. The company involves a proprietary ²¹²Pb production technology that provides access to alpha isotopes to accelerate the clinical development of drugs for prostate, skin, pancreatic, breast, bladder, colorectal, kidney, lung, and ovary cancer.
Key facts about AdvanCell
- Founded Year: 2019
- Location: Brisbane (Australia)
- Stage: Series D
- Total Funding till date: $444M
- Employee Count: 104 as on Sep 30, 2026
- Investors: Bain Capital Life Sciences, T. Rowe Price and 18 Others
- Latest Funding Round: Series D, Jun 30, 2026, $*****
- Highlight: Editors' Pick
Abingworth's Year-on-Year Investment Trends
Abingworth has invested in 135 companies over the last 29 years, with an average of 4 new investments annually in the last 10 years. In 2025, it made 9 investments, while as of Sep 2026, it has made 5 investments in this year. Its most recent first time investment was in Campfield Care and most recent follow-on round was in R1 Therapeutics.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 3 | 2 | 5 |
2025 | 5 | 4 | 9 |
2024 | 1 | 3 | 4 |
2023 | 5 | 1 | 6 |
2022 | 3 | 1 | 4 |
2021 | 6 | 1 | 7 |
2020 | 7 | 3 | 10 |
2019 | 2 | 2 | 4 |
2018 | 3 | 1 | 4 |
2017 | 2 | 3 | 5 |
Abingworth's Investments by Stage
Abingworth has made 38 investments in Series A stage with an average round size of $50.6M, 25 investments in Series B stage with an average round size of $39.6M and 14 investments in Series C stage with an average round size of $63.4M.Stage of entry | No. of Investments |
|---|---|
Series A | 38 |
Series B | 25 |
Series C | 14 |
Post IPO | 10 |
Series D | 8 |
Others | 6 |
Note: We have considered here, only first round of investments
Abingworth's Investments by Sector
Abingworth has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Sustainability Tech, Enterprise Applications and HealthTech. Notably, it has invested in 112 Tech companies, 100 Enterprise (B2B) companies, 24 Software companies and at least 10 companies focusing on Consumer (B2C).Sector | No. of Investments |
|---|---|
Life Sciences | 92 |
High Tech | 17 |
Sustainability Tech | 10 |
Enterprise Applications | 9 |
HealthTech | 9 |
Others | 12 |
Note: We have considered here, only first round of investments
Abingworth's Investments by Geography
Abingworth has made most investments in United States (64), followed by United Kingdom where it has made 15 investments.Country | No. of Investments |
|---|---|
United States | 64 |
United Kingdom | 15 |
France | 5 |
Switzerland | 5 |
Belgium | 3 |
Others | 9 |
Note: We have considered here, only first round of investments
Abingworth's recent investments
Abingworth has made 5 investments in 2026 so far. R1 Therapeutics and AdvanCell are the latest among them.Here are the most recent investments by Abingworth:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Sep 30, 2026 | United States | Series A | 7093 | [+5] | |
Jun 30, 2026 | Australia | Series D | 2508 | [+17] | |
May 20, 2026 | United States | Series A | 5310 | ||
May 05, 2026 | United Kingdom | Series A | 8532 | [+8] | |
Mar 17, 2026 | United States | Series A | 3052 | [+4] |
IPOs and Publicly Listed companies in Abingworth's Portfolio
30 of Abingworth's portfolio companies have become public. Iambic Therapeutics got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Oct 2026 and HilleVax got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $538M.Here are Abingworth's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Oct 15, 2026 | Oct 03, 2023 | Series B | 2094 | |
Apr 29, 2022 | Sep 08, 2021 | Series D | 8335 | |
Dec 09, 2021 | May 27, 2020 | Series A | 5336 | |
Sep 24, 2021 | Aug 30, 2006 | Series F | 6217 | |
May 14, 2021 | Oct 29, 2020 | Series C | 9405 |
Acquired companies in Abingworth's Portfolio
54 companies from Abingworth's portfolio have been acquired. The most recent acquisition was Personalis in Jul 2026 by Tempus for $*****.Here are Abingworth's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jul 20, 2026 | Oct 01, 2011 | Series A | 5013 | |
Jul 06, 2026 | Jul 08, 2024 | Series A | 8396 | |
Apr 06, 2026 | - | - | 9922 | |
Jul 09, 2025 | Jun 17, 2016 | Series C | 9634 | |
Oct 14, 2024 | Jan 24, 2007 | Series B | 2275 |
Team profile of Abingworth
Abingworth has a team of 20 members including 8 Partners, 1 Venture Partner and 2 Principals located in United Kingdom, United States and 1 more location. Abingworth's team does not sit on the board of any company as of now.Here is a list of top team members in Abingworth:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Seattle | - | ||
Partner | London | - | ||
Partner | United Kingdom | - | - | |
Partner | London | - | ||
Partner | New York City | - | ||
Partner | Skibbereen | - | ||
Partner | New York City | - | ||
Partner | Menlo Park | - | - | |
Venture Partner | Chicago | - |
Co-investors of Abingworth
Over the past 29 years, 630 investors have co-invested in Abingworth's portfolio companies. This includes funds and angels.
- Invested before Abingworth: HHS, Versant Ventures and 138 others have invested in rounds before Abingworth. There are 4 companies where HHS has invested before Abingworth and 4 companies where Versant Ventures has invested before Abingworth.
- Top Co-investors of Abingworth: 250 investors entered a company along with Abingworth. These include investors like Novo Holdings (8 companies).
- Invested after Abingworth: A total of 240 investors have invested in Abingworth's portfolio after their investments. Top Investors include RA Capital Management (4 companies), HHS (4 companies) and Bain Capital Life Sciences (4 companies).
Recent News related to Abingworth
•
Redx Pharma Secures $36 Million Series A Funding for Cancer and Fibrotic Disease TherapeuticsInsider Media•Aug 28, 2026•Abingworth, Insider Media, Redx Pharma, Dark Peak Analytics
•
cAMPfield harvests $180M series A to advance oral IBD drug licensed from NewsoaraFierce Biotech•Jun 18, 2026•Campfield Care, Novo Holdings, Venrock, Abingworth and 2 others
•
4BIO Capital leads oversubscribed £61 million Series A financing for Cytospire TherapeuticsGlobeNewswire•May 05, 2026•Cytospire Therapeutics, 4Bio Capital, Criteria Bio Ventures, LifeArc Ventures and 4 others
•
Renal Disease Biotech R1 Therapeutics Nabs $77.5M for Phase 2bEndpoints•Mar 17, 2026•R1 Therapeutics, Alebund, Curie.Bio, DaVita Venture Group and 3 others
•
•
Addition Therapeutics Announces $100 Million Funding for Genomic MedicineBenzinga•Dec 17, 2025•Abingworth, Addition Therapeutics, SR One, Pivotal Life Sciences and 3 others
•
Solve Therapeutics Raises $120 Million to Develop Best-in-Class ADCs for Solid TumorsBusiness Wire•Nov 17, 2025•B Capital, Balyasny Asset Management, Ally Bridge Group, Alexandria and 10 others
•
•
Antares Therapeutics Launches With $177 Million to Develop Precision Cancer MedicinesPulse 2.0•Jun 17, 2025•Antares, Omega Funds, Atlas Venture, Lightspeed Venture Partners and 7 others
•
Glycomine raises $115m to advance rare disease therapy into Phase IIb
Pharmaceutical Technology•Apr 16, 2025•Glycomine, CTI Life Sciences Fund, Advent Life Sciences, Novo Holdings and 7 others
